Fasting Plasma Glucose Monitoring in Older Adults Targeting Lower HbA1c
No, fasting plasma glucose is not always recommended when managing older adults targeting lower HbA1c—the monitoring approach should be based on treatment intensity, hypoglycemia risk, and functional status rather than applied universally.
Key Monitoring Framework
The American Geriatrics Society guidelines 1 establish that self-monitoring of blood glucose (including fasting measurements) should be individualized based on:
- Goals of care and target HbA1c levels
- Potential for modifying therapy
- Risk of hypoglycemia
- Functional and cognitive abilities
Importantly, the guidelines explicitly state that "some people do not need to self-monitor" and must balance monitoring with intensity of therapy, quality of life, and hypoglycemia risk 1.
When Fasting Glucose Monitoring IS Recommended
Increase monitoring frequency when:
- Using insulin or oral agents that cause hypoglycemia (sulfonylureas, meglitinides) 1
- Adding to or modifying therapy 1
- Symptomatic with high HbA1c levels requiring tight control 1
- History of severe or frequent hypoglycemia 1
When Fasting Glucose Monitoring May NOT Be Necessary
Consider reducing or eliminating routine fasting glucose checks for:
- Stable older adults on metformin monotherapy without hypoglycemia risk
- Those with HbA1c stable over several years (HbA1c monitoring every 12 months may suffice) 1, 2
- Frail older adults with higher HbA1c targets (8-9%) on low-intensity regimens 1
- Patients with cognitive or functional impairment where monitoring burden outweighs benefits 1
Critical Context: Targeting LOWER HbA1c Increases Risk
The evidence strongly cautions against aggressive lowering of HbA1c in older adults:
- Potential harm exists when lowering HbA1c below 6.5% in older adults with type 2 diabetes (Level IIA evidence) 1
- No evidence supports using medications to achieve tight glycemic control in older adults 1
- Intensive treatment targeting HbA1c <6.0% significantly increases hypoglycemia requiring assistance 3
Recommended HbA1c targets are:
- 7.5-8% for most older adults 1
- 7-7.5% only if safely achievable in healthy older adults with few comorbidities 1
- 8-9% for those with multiple comorbidities, poor health, or limited life expectancy 1
Modern Alternative: Continuous Glucose Monitoring
The 2023-2025 ADA Standards 3, 4 recommend:
- CGM for older adults with type 1 diabetes to reduce hypoglycemia and treatment burden
- Consider CGM for older adults with type 2 diabetes on insulin to improve outcomes and reduce hypoglycemia
- CGM demonstrated 27 minutes/day less hypoglycemia in adults over 60 with type 1 diabetes 3
This represents a paradigm shift away from routine fasting glucose finger-sticks toward continuous monitoring when intensive management is warranted.
Practical Algorithm
For older adults targeting lower HbA1c:
If on insulin or sulfonylureas: Self-monitoring (including fasting glucose) is recommended to detect hypoglycemia 1
If on metformin alone or low-risk agents: Routine fasting glucose monitoring is optional; rely on periodic HbA1c (every 6-12 months) 1, 2
If cognitively impaired or frail: Simplify monitoring; consider CGM if on insulin to reduce caregiver burden 3, 4
When adjusting therapy: Temporarily increase monitoring frequency regardless of baseline regimen 1
Common Pitfalls to Avoid
- Over-monitoring stable patients: Creates unnecessary burden without improving outcomes
- Pursuing HbA1c <7% aggressively: Increases hypoglycemia risk, which worsens cognitive function and mortality in older adults 3
- Ignoring functional status: Patients unable to respond appropriately to glucose readings should not self-monitor 1
- Using fasting glucose alone for diagnosis: The 2019 Endocrine Society guideline 5 recommends fasting plasma glucose AND/OR HbA1c for screening, recognizing both have limitations
The evidence clearly shows that monitoring intensity should match treatment intensity and hypoglycemia risk, not be applied universally based solely on pursuing lower HbA1c targets.